Download PDFPDF

Melatonin may decrease risk for and aid treatment of COVID-19 and other RNA viral infections
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    High dose melatonin monotherapy for COVID

    The use of high dose melatonin early and aggressively for those infected with COVID-19 was the subject of an international symposium held in December 2020 (1). Dr Richard Neel reported on over 1000 cases that have responded to monotherapy with melatonin.
    Why this works, as speculated upon in this article, is open to debate. What is most important is that people can benefit from this treatment modality. Thank you for the opportunity to raise awareness of this underappreciated therapeutic option.

    Conflict of Interest:
    None declared.